Tourmaline Bio, Inc.
TRML
$15.10
-$0.64-4.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.97M | -22.24M | -20.18M | -17.49M | -13.31M |
| Total Depreciation and Amortization | 12.00K | 9.00K | 10.00K | 10.00K | 10.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 753.00K | -197.00K | -432.00K | -497.00K | 188.00K |
| Change in Net Operating Assets | 526.00K | 1.53M | -2.85M | -33.00K | -1.81M |
| Cash from Operations | -21.68M | -20.89M | -23.44M | -18.01M | -14.92M |
| Capital Expenditure | -9.00K | -9.00K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.95M | 16.40M | -11.70M | -10.13M | -188.87M |
| Cash from Investing | 25.94M | 16.39M | -11.70M | -10.13M | -188.87M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 569.00K | 0.00 | 0.00 | 0.00 | 161.35M |
| Repurchase of Common Stock | -7.00K | -3.00K | -1.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 562.00K | -3.00K | -1.00K | 0.00 | 161.35M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.82M | -4.50M | -35.14M | -28.14M | -42.44M |